Current Cardiology Reports

, 20:131 | Cite as

Diagnosis and Management of Chagas Cardiomyopathy in the United States

  • Lillian Benck
  • Evan Kransdorf
  • Jignesh PatelEmail author
Heart Failure (HJ Eisen, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Heart Failure


Purpose of Review

Chagas cardiomyopathy is an emerging form of non-ischemic cardiomyopathy in the USA. This review aims to summarize current concepts in pathophysiology, disease transmission, medical therapy, and heart transplantation for patients with chronic Chagas cardiomyopathy.

Recent Findings

The incidence of Chagas cardiomyopathy is increasing in the USA, driven mainly by immigration from countries where Chagas disease is endemic. Chagas cardiomyopathy is a chronic, progressive myocarditis, with hallmark features of biventricular dysfunction, ventricular arrhythmias, thromboembolic complications, and a high risk of mortality. Currently, there is no effective treatment for chronic Chagas cardiomyopathy. Heart transplantation is the only treatment for patients with end-stage Chagas cardiomyopathy, but is associated with unique challenges including risk of reactivation.


As the prevalence of Chagas cardiomyopathy increases in the USA, practitioners must be aware of the unique challenges in diagnosis and management that Chagas cardiomyopathy presents.


Chagas cardiomyopathy Trypanosoma cruzi Myocarditis Trypanocidal therapy Heart transplantation Reactivation 


Compliance with Ethical Standards

Conflict of Interest

Lillian Benck, Evan Kransdorf, and Jignesh Patel declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602. Scholar
  2. 2.
    Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388–402. Scholar
  3. 3.
    Teixeira AR, Nascimento RJ, Sturm NR. Evolution and pathology in Chagas disease: a review. Mem Inst Oswaldo Cruz. 2006;101:463–91.CrossRefGoogle Scholar
  4. 4.
    Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ disease in the United States. Clin Microbiol Rev. 2011;24(4):655–81. Scholar
  5. 5.
    Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med. 2008;8(6):510–8.CrossRefGoogle Scholar
  6. 6.
    Schmunis GA, Yadon ZE. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 2010;115(1):14–21. Scholar
  7. 7.
    Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49(5):e52–e4. Scholar
  8. 8.
    Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. The American Journal of Tropical Medicine and Hygiene. 2015;93(1):108–13. Scholar
  9. 9.
    Meymandi SK, Forsyth CJ, Soverow J, Hernandez S, Sanchez D, Montgomery SP, et al. Prevalence of Chagas disease in the Latin American-born population of Los Angeles. Clin Infect Dis. 2017;64(9):1182–8. Scholar
  10. 10.
    Moncayo Á, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009;104:17–30.CrossRefGoogle Scholar
  11. 11.
    Gunter SM, Murray KO, Gorchakov R, Beddard R, Rossmann SN, Montgomery SP, et al. Likely autochthonous transmission of Trypanosoma cruzi to humans, South Central Texas, USA. Emerg Infect Dis. 2017;23(3):500–3. Scholar
  12. 12.
    Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, et al. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion. 2012;52(9):1922–30. Scholar
  13. 13.
    Leiby DA, Herron RM Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002;42(5):549–55. Scholar
  14. 14.
    Traina MI, Sanchez DR, Hernandez S, Bradfield JS, Labedi MR, Ngab TA, et al. Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles, California. Circulation: Heart Failure. 2015;8(5):938–43. Scholar
  15. 15.
    Kapelusznik L, Varela D, Montgomery SP, Shah AN, Steurer FJ, Rubinstein D, et al. Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis. 2013;57(1):e7–e. Scholar
  16. 16.
    Traina MI, Hernandez S, Sanchez DR, Dufani J, Salih M, Abuhamidah AM, et al. Prevalence of Chagas disease in a U.S. population of Latin American immigrants with conduction abnormalities on electrocardiogram. PLOS Negl Trop Dis. 2017;11(1):e0005244. Scholar
  17. 17.
    Vago AR, Andrade LO, Leite AA, d'Ávila Reis D, Macedo AM, Adad SJ, et al. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease. Am J Pathol. 2000;156(5):1805–9. Scholar
  18. 18.
    Sabino EC, Ribeiro AL, Salemi VMC, Di Lorenzo OC, Antunes AP, Menezes MM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation. 2013;127(10):1105–15. Scholar
  19. 19.
    • Kransdorf EP, Fishbein MC, LSC C, Patel JK, Velleca A, Tazelaar HD, et al. Pathology of chronic Chagas cardiomyopathy in the United States: a detailed review of 13 cardiectomy cases. Am J Clin Pathol. 2016;146(2):191–8. Kransdorf et al describe the gross and microscopic pathology of Chagas cardiomyopathy in the United States from a series of autopsy studies, noting that it is characterized by a myocarditis, with diffuse inflammatory cell infiltration. CrossRefPubMedGoogle Scholar
  20. 20.
    Reis DD, Apos A, Jones EM, Tostes S, Lopes ER, et al. Characterization of inflammatory infiltrates in chronic Chagasic myocardial lesions: presence of tumor necrosis factor-α+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg. 1993;48(5):637–44. Scholar
  21. 21.
    Gomes JAS, Bahia-Oliveira LMG, Rocha MOC, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R. Evidence that development of severe cardiomyopathy in human Chagas’ disease is due to a Th1-specific immune response. Infect Immun. 2003;71(3):1185–93. Scholar
  22. 22.
    Abel LCJ, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, et al. Chronic Chagas’ disease cardiomyopathy patients display an increased IFN-γ response to Trypanosoma cruzi infection. J Autoimmun. 2001;17(1):99–107. Scholar
  23. 23.
    Cunha-Neto E, Teixeira PC, Fonseca SG, Bilate AM, Kalil J. Myocardial gene and protein expression profiles after autoimmune injury in Chagas’ disease cardiomyopathy. Autoimmun Rev. 2011;10(3):163–5. Scholar
  24. 24.
    Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas’ disease. J Infect Dis. 1999;180(2):480–6. Scholar
  25. 25.
    Marcon GEB, Albuquerque DMD, Batista AM, Andrade PD, Almeida EA, Guariento ME, et al. Trypanosoma cruzi: parasite persistence in tissues in chronic chagasic Brazilian patients. Mem Inst Oswaldo Cruz. 2011;106:85–91.CrossRefGoogle Scholar
  26. 26.
    Añez N, Carrasco H, Parada H, Crisante G, Rojas A, Fuenmayor C, et al. Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg. 1999;60(5):726–32. Scholar
  27. 27.
    Belloti G, Bocchi EA, de Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J. 1996;131(2):301–7. Scholar
  28. 28.
    Benvenuti LA, Roggério A, Freitas HFG, Mansur AJ, Fiorelli A, Higuchi ML. Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trop Med Parasitol. 2008;102(6):481–7. Scholar
  29. 29.
    Borges DC, Araújo NM, Cardoso CR, Lazo Chica JE. Different parasite inocula determine the modulation of the immune response and outcome of experimental Trypanosoma cruzi infection. Immunology. 2013;138(2):145–56. Scholar
  30. 30.
    Freitas HFG, Chizzola PR, Paes ÂT, Lima ACP, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int J Cardiol. 2005;102(2):239–47. Scholar
  31. 31.
    Bertolino ND, Villafanha DF, Cardinalli-Neto A, Cordeiro JA, Arcanjo MJ, Theodoropoulos TAD, et al. Prognostic impact of Chagas’ disease in patients awaiting heart transplantation. J Heart Lung Transplant. 2010;29(4):449–53. Scholar
  32. 32.
    Rocha MOC, Nunes MCP, Ribeiro AL. Morbidity and prognostic factors in chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz. 2009;104:159–66.CrossRefGoogle Scholar
  33. 33.
    Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease. A systematic review of observational studies. Circulation. 2007;115(9):1101–8. Scholar
  34. 34.
    Ribeiro AL, Sabino EC, Marcolino MS, Salemi VMC, Ianni BM, Fernandes F, et al. Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors. PLoS Negl Trop Dis. 2013;7(2):e2078. Scholar
  35. 35.
    Strauss DG, Cardoso S, Lima JAC, Rochitte CE, Wu KC. ECG scar quantification correlates with cardiac magnetic resonance scar size and prognostic factors in Chagas’ disease. Heart. 2011;97(5):357–61. Scholar
  36. 36.
    Sarabanda AVL, Sosa E, Simões MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Ventricular tachycardia in Chagas’ disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms. Int J Cardiol. 2005;102(1):9–19. Scholar
  37. 37.
    Cardinalli-Neto AU, Greco OT, Bestetti RB. Automatic implantable cardioverter-defibrillators in Chagas’ heart disease patients with malignant ventricular arrhythmias. Pacing Clin Electrophysiol. 2006;29(5):467–70. Scholar
  38. 38.
    Sarabanda AV, Marin-Neto JA. Predictors of mortality in patients with Chagas’ cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2011;34(1):54–62. Scholar
  39. 39.
    Rassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355(8):799–808. Scholar
  40. 40.
    Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med. 2011;364(26):2527–34. Scholar
  41. 41.
    Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144(10):724–34. Scholar
  42. 42.
    Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64(6):1139–47. Scholar
  43. 43.
    •• Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–306. In this randomized control of over 2800 patients with Chagas' cardiomyopathy comparing benznidazole or placebo therapy the primary outcome of death, cardiac arrest, sustained ventricular tachycardia or insertion of a pacemaker or implantable defibrillator was not signfiicantly different between treatment and placebo groups, despite increased rates of conversion to a negative PCR in the benznidazole group. This highlights that trypanocidal treatment of Chagas cardiomyopathy with benznidazole does not significantly impact cardiac clinical outcomes. CrossRefPubMedGoogle Scholar
  44. 44.
    Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298(18):2171–81. Scholar
  45. 45.
    Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–908. Scholar
  46. 46.
    Lourenço AM, Faccini CC, Costa CAJ, Mendes GB, Fragata Filho AA. Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination. Rev Soc Bras Med Trop. 2018;51:52–6.CrossRefGoogle Scholar
  47. 47.
    Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira R, Caldera AR, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2006;49(3):892–9. Scholar
  48. 48.
    Vasconcelos JF, Souza BSF, Lins TFS, Garcia LMS, Kaneto CM, Sampaio GP, et al. Administration of granulocyte colony-stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy. FASEB J. 2013;27(12):4691–702. Scholar
  49. 49.
    Theodoropoulos TAD, Bestetti RB, Otaviano AP, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas’ heart disease in the current era of heart failure therapy. Int J Cardiol. 2008;128(1):22–9. Scholar
  50. 50.
    Cardinalli-Neto AU, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas’ heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2007;18(12):1236–40. Scholar
  51. 51.
    Nowicki MJ, Chinchilla C, Corado L, Matsuoka L, Selby R, Steurer F, et al. Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in Southern California: a population at risk. Transplantation. 2006;81(3):477–9. Scholar
  52. 52.
    Huprikar S, Bosserman E, Patel G, Moore A, Pinney S, Anyanwu A, et al. Donor-derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant. 2013;13(9):2418–25. Scholar
  53. 53.
    Kun H, Moore A, Mascola L, Frank S, Gena L, Kubak B, et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis. 2009;48(11):1534–40. Scholar
  54. 54.
    Schwartz BS, Paster M, Ison MG, Chin-Hong PV. Organ donor screening practices for Trypanosoma cruzi infection among US Organ Procurement Organizations. Am J Transplant. 2011;11(4):848–51. Scholar
  55. 55.
    Benatti RD, Oliveira GH, Bacal F. Heart transplantation for Chagas cardiomyopathy. J Heart Lung Transplant. 2017;36(6):597–603. Scholar
  56. 56.
    Bocchi EA, Fiorelli A. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant. 2001;20(6):637–45. Scholar
  57. 57.
    Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg. 2001;71(6):1833–8. Scholar
  58. 58.
    Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13(12):3262–8. Scholar
  59. 59.
    Godoy HL, Guerra CM, Viegas RF, Dinis RZ, Branco JN, Neto VA, et al. Infections in heart transplant recipients in Brazil: the challenge of Chagas’ disease. J Heart Lung Transplant. 2010;29(3):286–90. Scholar
  60. 60.
    Fernando B, Pereira SC, Vieira PP, Sandrigo M, Inacio FA, Groppo SN, et al. Transplantation for Chagas’ disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transpl. 2010;24(2):E29–34. Scholar
  61. 61.
    Fiorelli AI, Santos RHB, Oliveira JL, Lourenço-Filho DD, Dias RR, Oliveira AS, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc. 2011;43(1):220–4. Scholar
  62. 62.
    Campos SV, Strabelli TMV, Amato Neto V, Silva CP, Bacal F, Bocchi EA, et al. Risk factors for Chagas’ disease reactivation after heart transplantation. J Heart Lung Transplant. 2008;27(6):597–602. Scholar
  63. 63.
    Bacal F, Silva CP, Bocchi EA, Pires PV, Moreira LF, Issa VS, et al. Mychophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transpl. 2005;5(8):2017–21. Scholar
  64. 64.
    Bestetti RB, Souza TR, Lima MF, Theodoropoulos TAD, Cordeiro JA, Burdmann EA. Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas’ heart transplant recipients. Transplantation. 2007;84(3):441–2. Scholar
  65. 65.
    Fiorelli AI, Stolf NAG, Honorato R, Bocchi E, Bacal F, Uip D, et al. Later evolution after cardiac transplantation in Chagas’ disease. Transplant Proc. 2005;37(6):2793–8. Scholar
  66. 66.
    Maldonado C, Albano S, Vettorazzi L, Salomone O, Zlocowski JC, Abiega C, et al. Using polymerase chain reaction in early diagnosis of re-activated Trypanosoma cruzi infection after heart transplantation. J Heart Lung Transplant. 2004;23(12):1345–8. Scholar
  67. 67.
    Diez M, Favaloro L, Bertolotti A, Burgos JM, Vigliano C, Lastra MP, et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow-up in heart transplantation. Am J Transplant. 2007;7(6):1633–40. Scholar
  68. 68.
    Casadei DC. Chagas’ disease and solid organ transplantation. Transplant Proc. 2010;42(9):3354. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Smidt Heart InstituteCedars-Sinai Medical CenterBeverly HillsUSA

Personalised recommendations